Research-Studien

02.12.21  DGAP-Research-Studien: CEWE Stiftung & Co. KGaA
(von GSC Research GmbH): Kaufen
02.12.21  DGAP-Research-Studien: M1 Kliniken AG
(von First Berlin Equity Research GmbH): Buy
02.12.21  DGAP-Research-Studien: Bio-Gate AG
(von GBC AG): Kaufen
01.12.21  DGAP-Research-Studien: GBC Insider Focus Index
(von GBC AG): GBC Insider Focus Index
01.12.21  DGAP-Research-Studien: Rock Tech Lithium Inc.
(von Montega AG): Kaufen Rock Tech Lithium Inc.
01.12.21  DGAP-Research-Studien: Li-Metal Corp.
(von Sphene Capital GmbH): Buy
01.12.21  DGAP-Research-Studien: Erlebnis Akademie AG
(von Sphene Capital GmbH): Buy
30.11.21  DGAP-Research-Studien: clearvise AG
(von First Berlin Equity Research GmbH): Buy
30.11.21  DGAP-Research-Studien: sdm SE
(von GBC AG): Kaufen
29.11.21  DGAP-Research-Studien: Gold Mountain Mining Corp.
(von hanseatic stock publishing UG (haftungsbeschränkt)): Gold Mo [...]
29.11.21  DGAP-Research-Studien: MS Industrie AG
(von Montega AG): Kaufen
29.11.21  DGAP-Research-Studien: FORTEC Elektronik Aktiengesellschaft
(von Montega AG): Kaufen
29.11.21  DGAP-Research-Studien: IGEA Pharma N.V.
(von GBC AG): Kaufen
29.11.21  DGAP-Research-Studien: International School Augsburg -IS [...]
(von GBC AG): GBC Vorstandsinterview
26.11.21  DGAP-Research-Studien: 3U HOLDING AG
(von GSC Research GmbH): Halten
26.11.21  DGAP-Research-Studien: GK Software SE
(von Montega AG): Kaufen
25.11.21  DGAP-Research-Studien: Aroundtown SA
(von First Berlin Equity Research GmbH): Buy
25.11.21  DGAP-Research-Studien: asknet Solutions AG
(von Sphene Capital GmbH): Buy
24.11.21  DGAP-Research-Studien: MS Industrie AG
(von GBC AG): Kaufen
24.11.21  DGAP-Research-Studien: GBC Insider Focus Index
(von GBC AG): GBC Insider Focus Index

Indizes

GBC im Fokus

IGEA Pharma N.V. Realignment to CBD extraction

The goal is to become the quality and cost leader in the field of CBD in Europe. To this end, a GMP pharma compliant plant is being built in Switzerland. The supercritical CO2 extraction process is to be used to achieve the highest standard of quality. The CBD market is growing strongly and with the focus on quality leadership and pure extraction, IGEA Pharma's new business model should be able to occupy an attractive niche market. With the proprietary supercritical CO2-extraction technology, other markets such as vanilla, rose or rosemary can be developed in the medium term. Based on our DCF model, we have determined a fair value of € 1.05 (CHF 1.13) per share and assign a BUY rating.

News im Fokus

Allianz SE: Allianz kündigt Abschluss eines Rückversicherungsvertrages in den USA an

03. Dezember 2021, 07:03

Aktueller Webcast

Deutsche Konsum REIT-AG

FY 2020/2021 Financial Results

16. Dezember 2021

Aktuelle Research-Studie

CEWE Stiftung & Co. KGaA

Original-Research: CEWE Stiftung & Co. KGaA (von GSC Research GmbH): Kaufen

02. Dezember 2021